> top > docs > PubMed:32052831 > annotations

PubMed:32052831 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-148 Sentence denotes A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease.
T2 149-160 Sentence denotes BACKGROUND:
T3 161-248 Sentence denotes Anaerobic organisms are important pathogens in acute pelvic inflammatory disease (PID).
T4 249-378 Sentence denotes The currently recommended PID regimen of a single dose of ceftriaxone and doxycycline for 14 days has limited anaerobic activity.
T5 379-493 Sentence denotes The need for broader anaerobic coverage is unknown and concerns have been raised about metronidazole tolerability.
T6 494-502 Sentence denotes METHODS:
T7 503-718 Sentence denotes We conducted a randomized, double-blind, placebo-controlled trial comparing ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days, with or without 14 days of metronidazole in women with acute PID.
T8 719-795 Sentence denotes The primary outcome was clinical improvement at 3 days following enrollment.
T9 796-998 Sentence denotes Additional outcomes at 30 days following treatment were the presence of anaerobic organisms in the endometrium, clinical cure (absence of fever and reduction in tenderness), adherence, and tolerability.
T10 999-1007 Sentence denotes RESULTS:
T11 1008-1072 Sentence denotes We enrolled 233 women (116 to metronidazole and 117 to placebo).
T12 1073-1137 Sentence denotes Clinical improvement at 3 days was similar between the 2 groups.
T13 1138-1380 Sentence denotes At 30 days following treatment, anaerobic organisms were less frequently recovered from the endometrium in women treated with metronidazole than placebo (8% vs 21%, P < .05) and cervical Mycoplasma genitalium was reduced (4% vs 14%, P < .05).
T14 1381-1477 Sentence denotes Pelvic tenderness was also less common among women receiving metronidazole (9% vs 20%, P < .05).
T15 1478-1544 Sentence denotes Adverse events and adherence were similar in each treatment group.
T16 1545-1557 Sentence denotes CONCLUSIONS:
T17 1558-1812 Sentence denotes In women treated for acute PID, the addition of metronidazole to ceftriaxone and doxycycline was well tolerated and resulted in reduced endometrial anaerobes, decreased M. genitalium, and reduced pelvic tenderness compared to ceftriaxone and doxycycline.
T18 1813-1926 Sentence denotes Metronidazole should be routinely added to ceftriaxone and doxycycline for the treatment of women with acute PID.
T19 1927-1969 Sentence denotes CLINICAL TRIALS REGISTRATION: NCT01160640.
T1 0-148 Sentence denotes A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease.
T2 149-160 Sentence denotes BACKGROUND:
T3 161-248 Sentence denotes Anaerobic organisms are important pathogens in acute pelvic inflammatory disease (PID).
T4 249-378 Sentence denotes The currently recommended PID regimen of a single dose of ceftriaxone and doxycycline for 14 days has limited anaerobic activity.
T5 379-493 Sentence denotes The need for broader anaerobic coverage is unknown and concerns have been raised about metronidazole tolerability.
T6 494-502 Sentence denotes METHODS:
T7 503-718 Sentence denotes We conducted a randomized, double-blind, placebo-controlled trial comparing ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days, with or without 14 days of metronidazole in women with acute PID.
T8 719-795 Sentence denotes The primary outcome was clinical improvement at 3 days following enrollment.
T9 796-998 Sentence denotes Additional outcomes at 30 days following treatment were the presence of anaerobic organisms in the endometrium, clinical cure (absence of fever and reduction in tenderness), adherence, and tolerability.
T10 999-1007 Sentence denotes RESULTS:
T11 1008-1072 Sentence denotes We enrolled 233 women (116 to metronidazole and 117 to placebo).
T12 1073-1137 Sentence denotes Clinical improvement at 3 days was similar between the 2 groups.
T13 1138-1380 Sentence denotes At 30 days following treatment, anaerobic organisms were less frequently recovered from the endometrium in women treated with metronidazole than placebo (8% vs 21%, P < .05) and cervical Mycoplasma genitalium was reduced (4% vs 14%, P < .05).
T14 1381-1477 Sentence denotes Pelvic tenderness was also less common among women receiving metronidazole (9% vs 20%, P < .05).
T15 1478-1544 Sentence denotes Adverse events and adherence were similar in each treatment group.
T16 1545-1557 Sentence denotes CONCLUSIONS:
T17 1558-1812 Sentence denotes In women treated for acute PID, the addition of metronidazole to ceftriaxone and doxycycline was well tolerated and resulted in reduced endometrial anaerobes, decreased M. genitalium, and reduced pelvic tenderness compared to ceftriaxone and doxycycline.
T18 1813-1926 Sentence denotes Metronidazole should be routinely added to ceftriaxone and doxycycline for the treatment of women with acute PID.
T19 1927-1969 Sentence denotes CLINICAL TRIALS REGISTRATION: NCT01160640.

yangbin123xm_800_3

Id Subject Object Predicate Lexical cue
T1 214-241 DP denotes pelvic inflammatory disease
T10 307-318 CI denotes ceftriaxone
T11 1623-1634 CI denotes ceftriaxone
T12 1784-1795 CI denotes ceftriaxone
T13 1856-1867 CI denotes ceftriaxone
T14 628-639 CI denotes doxycycline
T15 323-334 CI denotes doxycycline
T16 1639-1650 CI denotes doxycycline
T17 1800-1811 CI denotes doxycycline
T18 1872-1883 CI denotes doxycycline
T19 33-44 CI denotes Ceftriaxone
T2 120-147 DP denotes Pelvic Inflammatory Disease
T20 78-91 CI denotes Metronidazole
T21 1813-1826 CI denotes Metronidazole
T22 680-693 CI denotes metronidazole
T23 466-479 CI denotes metronidazole
T24 1038-1051 CI denotes metronidazole
T25 1264-1277 CI denotes metronidazole
T26 1442-1455 CI denotes metronidazole
T27 1606-1619 CI denotes metronidazole
T3 243-246 DP denotes PID
T4 275-278 DP denotes PID
T5 714-717 DP denotes PID
T6 1585-1588 DP denotes PID
T7 1922-1925 DP denotes PID
T8 49-60 CI denotes Doxycycline
T9 579-590 CI denotes ceftriaxone
T28 1283-1290 CI denotes placebo
T30 1063-1070 CI denotes placebo

chenxin_473849_800_3

Id Subject Object Predicate Lexical cue
T1 1038-1051 CI denotes metronidazole
T2 466-479 CI denotes metronidazole
T3 680-693 CI denotes metronidazole
T4 1264-1277 CI denotes metronidazole
T5 1442-1455 CI denotes metronidazole
T6 1606-1619 CI denotes metronidazole
T7 78-91 CI denotes Metronidazole
T8 1813-1826 CI denotes Metronidazole
T9 1063-1070 CI denotes placebo
T11 1283-1290 CI denotes placebo
T12 307-318 CI denotes ceftriaxone
T13 579-590 CI denotes ceftriaxone
T14 1623-1634 CI denotes ceftriaxone
T15 1784-1795 CI denotes ceftriaxone
T16 1856-1867 CI denotes ceftriaxone
T17 33-44 CI denotes Ceftriaxone
T18 49-60 CI denotes Doxycycline
T19 323-334 CI denotes doxycycline
T20 628-639 CI denotes doxycycline
T21 1639-1650 CI denotes doxycycline
T22 1800-1811 CI denotes doxycycline
T23 1872-1883 CI denotes doxycycline
T24 214-241 DP denotes pelvic inflammatory disease
T25 120-147 DP denotes Pelvic Inflammatory Disease
T26 243-246 DP denotes PID
T27 275-278 DP denotes PID
T28 714-717 DP denotes PID
T29 1585-1588 DP denotes PID
T30 1922-1925 DP denotes PID